Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: a new anticancer drug?

Massimo Fanelli1, Roberta Sarmiento, Domenico Gattuso

  • 1Division of Clinical Oncology, San Filippo Neri Hospital, Rome, Italy.

Expert Opinion on Investigational Drugs
|July 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

Experimental hematology & oncology·2026
Same author

Eosinophil-linked pulmonary circulation in EGPA Improves under anti-IL-5/R therapy: A longitudinal study.

European journal of internal medicine·2026
Same author

Inborn errors of immunity: a structured model for paediatric-to-adult transition of care.

Frontiers in immunology·2026
Same author

Navigating primary and secondary immunodeficiency intersections: how to find IEI hidden within SID.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2026
Same author

Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.

Lupus science & medicine·2026
Same author

Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis.

Annals of hematology·2026

Thalidomide (Thal) shows anticancer properties by inhibiting tumor growth and stimulating immune responses. It is most effective against multiple myeloma and shows moderate activity in certain solid tumors, with generally manageable side effects.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • Thalidomide (Thal), initially a sedative, exhibits significant antitumoural properties.
  • Its mechanisms include inhibiting angiogenesis, modulating cytokine pathways, and enhancing immune responses.
  • Thalidomide is currently under clinical evaluation for various cancer treatments.

Purpose of the Study:

  • To provide a comprehensive overview of thalidomide's efficacy and toxicity in cancer patients.
  • To summarize current literature on thalidomide's use in oncology.
  • To identify the most responsive malignancies and potential combination therapies.

Main Methods:

  • Literature review of experimental and clinical studies on thalidomide in cancer.
  • Analysis of data regarding antitumour activity and toxicity profiles.

Related Experiment Videos

  • Evaluation of thalidomide's effectiveness as a monotherapy and in combination regimens.

    • Main Results:

    • Multiple myeloma demonstrates the highest responsiveness to thalidomide therapy.
    • Moderate activity observed in solid tumors like glioblastoma multiforme, renal cell carcinoma, and malignant melanoma.
    • Peripheral neuropathy is the primary dose-dependent toxicity; common side effects include somnolence, constipation, dizziness, and fatigue.

    Conclusions:

    • Thalidomide exhibits promising anticancer activity, particularly in multiple myeloma.
    • Further research is necessary to fully elucidate its role, alone or in combination therapies.
    • Combinations with corticosteroids, cytotoxic drugs, chemotherapy, radiation, and targeted agents are under investigation for various cancers.